{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T06:58:41Z","timestamp":1773212321150,"version":"3.50.1"},"reference-count":35,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,9,29]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>Fc\u03bcR is a more selective target for the CAR T-cell therapy of CLL compared with currently used targets, including CD19.<\/jats:p>","DOI":"10.1182\/blood-2016-01-692046","type":"journal-article","created":{"date-parts":[[2016,8,18]],"date-time":"2016-08-18T03:04:32Z","timestamp":1471489472000},"page":"1711-1722","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":53,"title":["Chimeric antigen receptor T cells targeting Fc \u03bc receptor selectively eliminate CLL cells while sparing healthy B cells"],"prefix":"10.1182","volume":"128","author":[{"given":"Elena","family":"Faitschuk","sequence":"first","affiliation":[{"name":"Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany;"},{"name":"Department I Internal Medicine, University Hospital Cologne, Cologne, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas A.","family":"Hombach","sequence":"additional","affiliation":[{"name":"Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany;"},{"name":"Department I Internal Medicine, University Hospital Cologne, Cologne, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas P.","family":"Frenzel","sequence":"additional","affiliation":[{"name":"Department I Internal Medicine, University Hospital Cologne, Cologne, Germany;"},{"name":"Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, Cologne, Germany; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clemens-Martin","family":"Wendtner","sequence":"additional","affiliation":[{"name":"Department I Internal Medicine, University Hospital Cologne, Cologne, Germany;"},{"name":"Klinikum Schwabing, Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hinrich","family":"Abken","sequence":"additional","affiliation":[{"name":"Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany;"},{"name":"Department I Internal Medicine, University Hospital Cologne, Cologne, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"30","key":"2019111902371654300_B1","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1200\/JCO.2007.15.4757","article-title":"Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.","volume":"26","author":"Sorror","year":"2008","journal-title":"J Clin Oncol"},{"issue":"26","key":"2019111902371654300_B2","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1182\/blood-2014-07-586826","article-title":"Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?","volume":"124","author":"Dreger","year":"2014","journal-title":"Blood"},{"issue":"9980","key":"2019111902371654300_B3","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1016\/S0140-6736(15)60027-7","article-title":"Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial.","volume":"385","author":"Hillmen","year":"2015","journal-title":"Lancet"},{"issue":"12","key":"2019111902371654300_B4","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med"},{"issue":"26","key":"2019111902371654300_B5","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1200\/JCO.2011.39.2688","article-title":"Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.","volume":"30","author":"Fischer","year":"2012","journal-title":"J Clin Oncol"},{"issue":"18","key":"2019111902371654300_B6","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2005.12.051","article-title":"Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.","volume":"23","author":"Keating","year":"2005","journal-title":"J Clin Oncol"},{"issue":"9747","key":"2019111902371654300_B7","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"issue":"3","key":"2019111902371654300_B8","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.","volume":"371","author":"Byrd","year":"2014","journal-title":"N Engl J Med"},{"issue":"22","key":"2019111902371654300_B9","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood-2013-11-535047","article-title":"Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110\u03b4, for relapsed\/refractory chronic lymphocytic leukemia.","volume":"123","author":"Brown","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2019111902371654300_B10","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1182\/blood-2015-03-585075","article-title":"Targeted therapies in CLL: mechanisms of resistance and strategies for management.","volume":"126","author":"Woyach","year":"2015","journal-title":"Blood"},{"issue":"4","key":"2019111902371654300_B11","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/sji.12331","article-title":"CD19-Chimeric Antigen Receptor T Cells for Treatment of Chronic Lymphocytic Leukaemia and Acute Lymphoblastic Leukaemia.","volume":"82","author":"Lorentzen","year":"2015","journal-title":"Scand J Immunol"},{"issue":"10","key":"2019111902371654300_B12","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1182\/blood-2008-05-157255","article-title":"Overexpression of TOSO in CLL is triggered by B-cell receptor signaling and associated with progressive disease.","volume":"112","author":"Pallasch","year":"2008","journal-title":"Blood"},{"issue":"8","key":"2019111902371654300_B13","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.4049\/jimmunol.1100532","article-title":"TOSO, the Fcmicro receptor, is highly expressed on chronic lymphocytic leukemia B cells, internalizes upon IgM binding, shuttles to the lysosome, and is downregulated in response to TLR activation.","volume":"187","author":"Vire","year":"2011","journal-title":"J Immunol"},{"issue":"2","key":"2019111902371654300_B14","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1182\/blood-2007-11-124065","article-title":"SAGE analysis demonstrates increased expression of TOSO contributing to Fas-mediated resistance in CLL.","volume":"112","author":"Proto-Siqueira","year":"2008","journal-title":"Blood"},{"issue":"19","key":"2019111902371654300_B15","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1182\/blood-2014-07-586511","article-title":"miRs-138 and -424 control palmitoylation-dependent CD95-mediated cell death by targeting acyl protein thioesterases 1 and 2 in CLL.","volume":"125","author":"Berg","year":"2015","journal-title":"Blood"},{"issue":"6","key":"2019111902371654300_B16","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1073\/pnas.1009069108","article-title":"Eradication of melanomas by targeted elimination of a minor subset of tumor cells.","volume":"108","author":"Schmidt","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"2019111902371654300_B17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1399-0039.1996.tb02509.x","article-title":"Rapid and reliable cloning of antibody variable regions and generation of recombinant single chain antibody fragments.","volume":"47","author":"Gilliland","year":"1996","journal-title":"Tissue Antigens"},{"issue":"7","key":"2019111902371654300_B18","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.4049\/jimmunol.178.7.4650","article-title":"T cell activation by antibody-like immunoreceptors: the position of the binding epitope within the target molecule determines the efficiency of activation of redirected T cells.","volume":"178","author":"Hombach","year":"2007","journal-title":"J Immunol"},{"issue":"11","key":"2019111902371654300_B19","doi-asserted-by":"crossref","first-page":"6123","DOI":"10.4049\/jimmunol.167.11.6123","article-title":"Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28\/CD3 zeta signaling receptor molecule.","volume":"167","author":"Hombach","year":"2001","journal-title":"J Immunol"},{"issue":"8","key":"2019111902371654300_B20","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1182\/blood-2009-05-223586","article-title":"A novel Rag2-\/-gammac-\/--xenograft model of human CLL.","volume":"115","author":"Bertilaccio","year":"2010","journal-title":"Blood"},{"issue":"12","key":"2019111902371654300_B21","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1084\/jem.20091107","article-title":"Identity of the elusive IgM Fc receptor (FcmuR) in humans.","volume":"206","author":"Kubagawa","year":"2009","journal-title":"J Exp Med"},{"issue":"3","key":"2019111902371654300_B22","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/intimm\/dxp121","article-title":"Identification of TOSO\/FAIM3 as an Fc receptor for IgM.","volume":"22","author":"Shima","year":"2010","journal-title":"Int Immunol"},{"issue":"9","key":"2019111902371654300_B23","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/nm0997-984","article-title":"Acquired CD40-ligand deficiency in chronic lymphocytic leukemia.","volume":"3","author":"Cantwell","year":"1997","journal-title":"Nat Med"},{"issue":"18","key":"2019111902371654300_B24","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2011-04-350793","article-title":"Enhanced levels of both the membrane-bound and soluble forms of IgM Fc receptor (Fc\u03bcR) in patients with chronic lymphocytic leukemia.","volume":"118","author":"Li","year":"2011","journal-title":"Blood"},{"issue":"4","key":"2019111902371654300_B25","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1053\/j.gastro.2012.06.037","article-title":"T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice.","volume":"143","author":"Chmielewski","year":"2012","journal-title":"Gastroenterology"},{"issue":"2","key":"2019111902371654300_B26","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/sj.gt.3300813","article-title":"A chimeric receptor that selectively targets membrane-bound carcinoembryonic antigen (mCEA) in the presence of soluble CEA.","volume":"6","author":"Hombach","year":"1999","journal-title":"Gene Ther"},{"issue":"6","key":"2019111902371654300_B27","first-page":"1116","article-title":"An anti-CD30 chimeric receptor that mediates CD3-zeta-independent T-cell activation against Hodgkin\u2019s lymphoma cells in the presence of soluble CD30.","volume":"58","author":"Hombach","year":"1998","journal-title":"Cancer Res"},{"key":"2019111902371654300_B28","article-title":"Superior therapeutic index in lymphoma therapy: CD30+ CD34+ hematopoietic stem cells resist a chimeric antigen receptor T-cell attack [published online ahead of print 28 June 2016].","author":"Hombach","journal-title":"Mol Ther"},{"issue":"4","key":"2019111902371654300_B29","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/mt.2011.9","article-title":"CD28 costimulation Impairs the efficacy of a redirected t-cell antitumor attack in the presence of regulatory t cells which can be overcome by preventing Lck activation.","volume":"19","author":"Kofler","year":"2011","journal-title":"Mol Ther"},{"issue":"7","key":"2019111902371654300_B30","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.molmed.2012.04.009","article-title":"CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe.","volume":"18","author":"Gilham","year":"2012","journal-title":"Trends Mol Med"},{"issue":"12","key":"2019111902371654300_B31","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1158\/1078-0432.CCR-13-0330","article-title":"Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells.","volume":"19","author":"Hudecek","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"24","key":"2019111902371654300_B32","doi-asserted-by":"crossref","first-page":"7510","DOI":"10.1158\/0008-5472.CAN-14-2030","article-title":"Harnessing the fc\u03bc receptor for potent and selective cytotoxic therapy of chronic lymphocytic leukemia.","volume":"74","author":"Vire","year":"2014","journal-title":"Cancer Res"},{"issue":"22","key":"2019111902371654300_B33","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2010-05-283309","article-title":"The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor.","volume":"116","author":"Hudecek","year":"2010","journal-title":"Blood"},{"issue":"2","key":"2019111902371654300_B34","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1158\/2326-6066.CIR-14-0163","article-title":"Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells.","volume":"3","author":"Berger","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"2019111902371654300_B35","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1182\/blood-2015-03-585091","article-title":"A drive through cellular therapy for CLL in 2015: allogeneic cell transplantation and CARs.","volume":"126","author":"Mato","year":"2015","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/13\/1711\/1395609\/1711.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/13\/1711\/1395609\/1711.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T07:39:13Z","timestamp":1574149153000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/128\/13\/1711\/35389\/Chimeric-antigen-receptor-T-cells-targeting-Fc-%CE%BC"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,29]]},"references-count":35,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2016,9,29]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-01-692046","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,29]]}}}